GE HealthCare Technologies/$GEHC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GE HealthCare Technologies
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Ticker
$GEHC
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
53,000
ISIN
US36266G1076
Website
GEHC Metrics
BasicAdvanced
$33B
15.10
$4.76
1.38
$0.13
0.19%
Price and volume
Market cap
$33B
Beta
1.38
52-week high
$94.80
52-week low
$57.65
Average daily volume
3.5M
Dividend rate
$0.13
Financial strength
Current ratio
0.977
Quick ratio
0.7
Long term debt to equity
74.995
Total debt to equity
93.003
Dividend payout ratio (TTM)
2.61%
Interest coverage (TTM)
7.07%
Profitability
EBITDA (TTM)
3,761
Gross margin (TTM)
42.00%
Net profit margin (TTM)
11.03%
Operating margin (TTM)
16.13%
Effective tax rate (TTM)
18.51%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
6.07%
Return on equity (TTM)
26.44%
Valuation
Price to earnings (TTM)
15.103
Price to revenue (TTM)
1.657
Price to book
3.58
Price to tangible book (TTM)
-6.07
Price to free cash flow (TTM)
23.872
Free cash flow yield (TTM)
4.19%
Free cash flow per share (TTM)
301.15%
Dividend yield (TTM)
0.18%
Forward dividend yield
0.19%
Growth
Revenue change (TTM)
1.56%
Earnings per share change (TTM)
38.77%
3-year revenue growth (CAGR)
4.04%
3-year earnings per share growth (CAGR)
1.75%
What the Analysts think about GEHC
Analyst ratings (Buy, Hold, Sell) for GE HealthCare Technologies stock.
Bulls say / Bears say
GE HealthCare's diagnostic drug Flyrcado received FDA approval for detecting coronary artery disease, potentially expanding its market share in cardiac diagnostics. (reuters.com)
The company reported a 50.8% year-over-year increase in net income for Q1 2025, indicating strong financial performance. (google.com)
Analysts have set a consensus price target of $87.25 for GE HealthCare, suggesting a potential upside of approximately 24.9% from the current share price. (simplywall.st)
GE HealthCare reduced its 2024 revenue growth forecast due to a slowdown in China's healthcare sector, impacted by an anti-corruption campaign. (reuters.com)
The company faces stiff competition from major global players like Siemens Healthineers and Philips Healthcare, which could pressure market share and margins. (nasdaq.com)
GE HealthCare's business is affected by geopolitical tensions, including the ongoing war between Russia and Ukraine, leading to sanctions that impact operations in those regions. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
GEHC Financial Performance
Revenues and expenses
GEHC Earnings Performance
Company profitability
GEHC News
AllArticlesVideos
Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine
Business Wire·23 hours ago
GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions
Business Wire·1 week ago
ESTRO 2025 Congress: GE HealthCare to expand its radiation oncology portfolio and introduce new AI-enabled solutions
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GE HealthCare Technologies stock?
GE HealthCare Technologies (GEHC) has a market cap of $33B as of June 20, 2025.
What is the P/E ratio for GE HealthCare Technologies stock?
The price to earnings (P/E) ratio for GE HealthCare Technologies (GEHC) stock is 15.1 as of June 20, 2025.
Does GE HealthCare Technologies stock pay dividends?
Yes, the GE HealthCare Technologies (GEHC) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.13 and the yield is 0.19%. GE HealthCare Technologies has a payout ratio of 2.61% on a trailing twelve-month basis.
When is the next GE HealthCare Technologies dividend payment date?
The next GE HealthCare Technologies (GEHC) dividend payment date is unconfirmed.
What is the beta indicator for GE HealthCare Technologies?
GE HealthCare Technologies (GEHC) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.